HCVC leads kyron.bio €5.5M round to use glycan engineering for advanced drug design
Summary
In standard biomanufacturing, this process is highly inconsistent, producing a mix of glycan structures that can trigger immune responses or reduce therapeutic efficacy. Proprietary glycan-engineering toolbox: Engineering of the antibody therapeutic itself to prevent unwanted immune attack and enhance performance, while generating strong new intellectual property (IP).Together, these technologies allow kyron.bios platform to achieve over 97% consistency in glycan structures an unprecedented level compared to standard bioproduction methods.This level of glycan control unlocks transformative opportunities in antibody engineering, enabling biologic therapies that can resist degradation, evade immune detection, and target diseases with unprecedented specificity.The opportunity to partner with kyron.bio on drug design is especially pertinent to pharmaceutical companies working on next-generation monoclonal antibodies. McLaughlins experience studying rare single-cell organisms during her PhD at Institut Pasteur Paris has largely informed kyron.bios approach to drug development. The startup, under her leadership, has developed the first-ever scalable, patent-protected method to unlock this molecular design problem.Media images can be found here.About kyron.bio kyron.bio, based at Paris Biotech Sant\xe9 in the Cochin Hospital, pioneers precision control of glycosylation in antibody therapeutics to enhance functionality. Learn more at http://www.kyron.bio.About HCVCHCVC is an early-stage deeptech venture capital firm that backs founders turning frontier science into foundational industries.